Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma

Authors
Category Primary study
JournalCANCER RESEARCH
Year 2017
This article has no abstract
Epistemonikos ID: d1df767dbb43ea3866c1b0dd2c3cf2ba7841a2a4
First added on: Feb 08, 2025